Sartorius AG

EANS-Adhoc: Dynamic growth and overproportionate increase in profitability for the Biotechnology Division | Strong cyclical slump in demand and negative results for the Mechatronics Division | Robust consolidated operating earnings | One-time ...

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro   adhoc with the aim of a Europe-wide distribution. The issuer is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

Preliminary Figures for the First Half of 2009

24.07.2009

Order intake for the Biotechnology Division surged 8.8% (currency-adjusted: +5.8%) to 203.5 million euros (previous year: 187.1 mn euros) and sales revenue rose 7.4% (currency-adjusted: +4.3%) to 197.8 million euros from 184.1 mn euros a year ago. This gain was fueled by business with single-use products at clearly dou-ble-digit growth rates.

For the Mechatronics Division, order intake in the first six months fell cyclically from 124.1 million euros to 102.9 million euros (-17.1%; currency-adjusted:  20.3%). At the same time, sales revenue dropped from 119.9 million euros to 98.7 million euros (-17.7%; currency-adjusted: -20.9%).

On the whole, the Sartorius Group received orders valued at 306.4 million euros (311.3 mn euros), which equates to a decline of 1.6% (currency-adjusted: -4.6%). Consolidated sales revenue eased 2.5% (currency-adjusted: -5.6%) and is at 296.5 million euros (304.0 mn euros).

Consolidated earnings before interest, taxes and amortization and adjusted for one-time extraordinary expenses (underlying EBITA) are at 24.7 million euros (27.0 mn euros), which corresponds to a margin of 8.3% (8.9%). The Biotechnology Division contributed to this growth with 28.0 million euros (20.4 mn euros) and a margin increase from 11.1% to 14.2%. At -3.4 million euros (6.6 mn euros), the Mechatronics Division delivered negative earnings. One-time extraordinary expenses essentially entail provisions for the restructuring program currently being implemented in the Mechatronics Division, and total 16.3 million euros.

Without the two non-cash items of amortization and interest for share price warrants, consolidated underlying net profit after minority interest is at 6.4 million euros (9.6 mn euros); the corresponding earnings per share are at 0.37 euro (0.56 euro). Actual consolidated net profit after minority interest amounts to -8.1 million euros (7.3 mn euros). As of June 30, 2009, net debt was reduced to 181.9 million euros (Dec. 31, 2008: 217.6 mn euros).

For fiscal 2009, our forecast remains unchanged, with the Biotechnology Division´s revenue expected to grow and its earnings to increase overproportionately. For the Mechatronics Division, we project a double-digit decline in revenue and a negative earnings contribution. Given the continued high uncertainty regarding the global economy, we still consider it not possible to make a precise full-year forecast.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the first-half figures with analysts and investors on Tuesday, July 28, 2009, at 3:15 p.m. Central European Time (CET), in a teleconference. You may dial into the teleconference starting at 3:00 p.m. CET at the following numbers: Germany +49 (0)69 5007 1317; France +33 (0)1 70 99 43 01; UK +44 (0)20 7806 1966; USA +1 718 354 1389 The dial-in code is: 7760640 The webcast and presentation can be viewed at www.sartorius.com.

@@start.t2@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Andreas Wiederhold
Team Leader Treasury & Investor Relations
Telefon: +49 (0)551 308-1668
E-Mail: andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN:      DE0007165607
WKN:        716560
Index:    CDAX, Prime All Share, Technologie All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Hamburg / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              Hannover / free trade
              München / free trade



Weitere Meldungen: Sartorius AG

Das könnte Sie auch interessieren: